154 related articles for article (PubMed ID: 16101439)
1. DNA drug design for cancer therapy.
Cho-Chung YS
Curr Pharm Des; 2005; 11(22):2811-23. PubMed ID: 16101439
[TBL] [Abstract][Full Text] [Related]
2. Antisense DNAs as targeted genetic medicine to treat cancer.
Cho-Chung YS
Arch Pharm Res; 2003 Mar; 26(3):183-91. PubMed ID: 12723929
[TBL] [Abstract][Full Text] [Related]
3. Oligonucleotides as anticancer agents: from the benchside to the clinic and beyond.
Coppelli FM; Grandis JR
Curr Pharm Des; 2005; 11(22):2825-40. PubMed ID: 16101440
[TBL] [Abstract][Full Text] [Related]
4. Antisense oligonucleotides as therapeutics for malignant diseases.
Ho PT; Parkinson DR
Semin Oncol; 1997 Apr; 24(2):187-202. PubMed ID: 9129689
[TBL] [Abstract][Full Text] [Related]
5. Recent advances in the stereocontrolled synthesis of antisense phosphorothioates.
Lu Y
Mini Rev Med Chem; 2006 Mar; 6(3):319-30. PubMed ID: 16515471
[TBL] [Abstract][Full Text] [Related]
6. Antisense DNAs as targeted therapeutics for cancer: no longer a dream.
Cho-Chung YS
Curr Opin Investig Drugs; 2002 Jun; 3(6):934-9. PubMed ID: 12137417
[TBL] [Abstract][Full Text] [Related]
7. Antisense oligonucleotides: a new therapeutic approach.
Temsamani J; Guinot P
Biotechnol Appl Biochem; 1997 Oct; 26(2):65-71. PubMed ID: 9357101
[TBL] [Abstract][Full Text] [Related]
8. Oligonucleotide technologies: synthesis, production, regulations and applications. 29-30th November 2000, Hamburg, Germany.
Uhlmann E
Expert Opin Biol Ther; 2001 Mar; 1(2):319-28. PubMed ID: 11727539
[TBL] [Abstract][Full Text] [Related]
9. Locked nucleic acid holds promise in the treatment of cancer.
Frieden M; Ørum H
Curr Pharm Des; 2008; 14(11):1138-42. PubMed ID: 18473860
[TBL] [Abstract][Full Text] [Related]
10. Antisense anticancer oligonucleotide therapeutics.
Wang H; Prasad G; Buolamwini JK; Zhang R
Curr Cancer Drug Targets; 2001 Nov; 1(3):177-96. PubMed ID: 12188878
[TBL] [Abstract][Full Text] [Related]
11. [Antisense oligonucleotides: a new therapeutic approach].
Guinot P; Temsamani J
Pathol Biol (Paris); 1998 May; 46(5):347-54. PubMed ID: 9769897
[TBL] [Abstract][Full Text] [Related]
12. Antisense protein kinase A RI alpha-induced tumor reversion: portrait of a microarray.
Cho-Chung YS
Biochim Biophys Acta; 2004 Mar; 1697(1-2):71-9. PubMed ID: 15023351
[TBL] [Abstract][Full Text] [Related]
13. Antisense oligonucleotide-based therapeutics for cancer.
Dean NM; Bennett CF
Oncogene; 2003 Dec; 22(56):9087-96. PubMed ID: 14663487
[TBL] [Abstract][Full Text] [Related]
14. Preclinical and clinical pharmacology of antisense oligonucleotides.
Marcusson EG; Yacyshyn BR; Shanahan WR; Dean NM
Mol Biotechnol; 1999 Aug; 12(1):1-11. PubMed ID: 10554769
[TBL] [Abstract][Full Text] [Related]
15. Antisense therapy in oncology: new hope for an old idea?
Tamm I; Dörken B; Hartmann G
Lancet; 2001 Aug; 358(9280):489-97. PubMed ID: 11513935
[TBL] [Abstract][Full Text] [Related]
16. Synthetic oligonucleotides: useful molecules? A review.
Calogero A; Hospers GA; Mulder NH
Pharm World Sci; 1997 Dec; 19(6):264-8. PubMed ID: 9443167
[TBL] [Abstract][Full Text] [Related]
17. Applications of antisense oligonucleotides in oncology.
Pierga JY; Magdelenat H
Cell Mol Biol (Noisy-le-grand); 1994 May; 40(3):237-61. PubMed ID: 7920172
[TBL] [Abstract][Full Text] [Related]
18. Theoretical and experimental approaches to design effective antisense oligonucleotides.
Sczakiel G
Front Biosci; 2000 Jan; 5():D194-201. PubMed ID: 10702382
[TBL] [Abstract][Full Text] [Related]
19. [Therapeutic oligonucleotides: a review].
Wang X; Xian J; Chen G; Peng H
Sheng Wu Gong Cheng Xue Bao; 2018 May; 34(5):664-675. PubMed ID: 29893074
[TBL] [Abstract][Full Text] [Related]
20. Antisense oligonucleotides to p53 tumor suppressor suppress the induction of apoptosis by epidermal growth factor in NCI-H 596 human lung cancer cells.
Murayama Y; Horiuchi S
Antisense Nucleic Acid Drug Dev; 1997 Apr; 7(2):109-14. PubMed ID: 9149846
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
